Pfizer announced that Chantix (varenicline), a drug designed to help smokers quit smoking, is now available in US pharmacies. This is the first new prescription drug for smoking cessation treatment approved by the U.S. Food and Drug Administration (FDA) in a decade. When prescribed Chantix, smokers will be offered a chance to participate in a behavioral modification program called GETQUIT Support Plan at no extra cost.

Chantix acts on the areas of the brain affected by nicotine and helps those who smoke cigarettes to quit smoking in two ways: by providing some nicotine effects to ease the withdrawal symptoms and by blocking the effects of nicotine from cigarettes if they start smoking again. There is no magic bullet here, although in clinical trials the drug quadrupled the chances of a smoker quitting and was shown to be twice as effective as the currently prescribed drug Zyban.

Pfizer Helpful Answers has a program available for people without prescription coverage. People with low incomes may even qualify for free medications. For more information about Chantix and the free GETQUIT program, visit the Chantix website.

I can't decide what to do about my port now that my breast cancer treatment is over. It's been an on-going internal battle. I don't know whether I should leave it in place -- tunneled underneath the skin on my collarbone where it is available and accessible should I ever need further infusions of cancer-fighting drugs -- or whether I should have it removed since there is no real purpose for it right now. There is the issue of superstition and safety -- leaving it right where it is allows for easy use if cancer returns and prevents another surgery to implant a new one. But there is also the issue of moving on -- and removing it because I don't need it, because I may never need it. One doctor told me recently that it should come out because if it remains in my body, I risk infection. And anything foreign in my body for an extended period of time is not completely safe. But a cancer survivor told me that she had hers removed immediately after treatment and had to get a new one because her cancer recurred three months later.

I am accustomed to wrestling matches like this one -- like my stand-off between treatment with Taxol or without Taxol, between anti-depressant or no anti-depressant, between vegan diets and traditional diets. Sometimes I can make a good call. Sometimes I just can't decide. Like right now.

Right here in Gainesville, Florida -- at the University of Florida to be exact -- the vaccine for cervical cancer is now available for college students. This vaccine -- called Gardasil -- could prevent women from contracting the human papillomavirus (HPV) which can cause cervical cancer and genital warts. Almost 30 of the more than 100 different strains of HPV are sexually transmitted -- and sometime in their lives, 50 percent of sexually active men and women will contract genital HPV infection. Many will not know they have it and will spread it unknowingly to sexual partners. Protection can come in the form of Gardasil which is approved for use in women between the ages of 9 and 26.

Women who are not sexually active are the best candidates for this vaccine because it is clear that they have not yet been infected. The vaccine is not effective for women who already are infected with HPV. And those who don't know if they are infected can determine if they have HPV through a routine Pap smear. If they do not have HPV, the vaccine is indicated. Once the vaccine is indicated, it is delivered in three separate doses over a six-month period of time. Each dose costs $120 -- which may discourage students from this option.

About 9,700 women in the United States will develop cervical cancer in 2006 and this cancer will kill 3,700 of these women. This vaccine -- if received well by young women who can afford it -- should prove a breakthrough in cancer research and prevention.